RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end- products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.
“Inflammation is the driving force in many important diseases,” Professor Thomas said.
“RAGE is a key protein that amplifies inflammation, so targeting RAGE helps bring inflammation back under control.
“Often it’s not easy to turn inflammation down without disrupting pathways needed for good health. But RAGE only turns up when things are going wrong, which makes it such a great target.”
RAGE Biotech will test two novel approaches to modulate RAGE.